Please login to the form below

Not currently logged in
Email:
Password:

S-A wins award for malaria programme

Sanofi-aventis has won the 2010 Global Business Coalition Core Competence Award for its Malaria Access to Medicines programme

Sanofi-aventis (S-A) has won the 2010 Global Business Coalition Core Competence Award for the Malaria Access to Medicines programme – a campaign to combat the disease, devised in partnership with the Drugs for Neglected Diseases Initiative (DNDi).

The awards honour organisations who have shown pioneering skills and strategies in the fight against HIV/AIDS, tuberculosis and malaria.

Previous winners have included Warner Bros. Entertainment, who developed an action-based video game pilot that delivered targeted HIV prevention messages to East African youths, and the BBC World Service Trust for its mass media HIV/AIDS campaign in India.

The Malaria Access to Medicines Programme has seen S-A and not-for-profit product developers, DNDi, develop and distribute anti-malarial treatment, Coarsucam, or ASAQ (artesunate amodiaquine winthrop) in the poorest areas of sub-sharan Africa.

ASAQ is the first anti-malarial treatment to be aimed at such a patient group, in particular children.

The treatment costs less than $1 for an adult and less than $0.50 for children when distributed to non-profit organisations in the area.

More than 50 million ASAQ treatments have been distributed since 2008 when the treatment was pre-qualified by the World Health Organisation (WHO).

Commenting on the award, Global Business Coalition CEO, John Todstrom said: "The sanofi-aventis ASAQ programme has produced real results in helping to address one of the three greatest threats of our time. We congratulate them on their richly deserved success."

25th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics